These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 8950362)

  • 1. Clearance rate of serum-free and total PSA following radical retropubic prostatectomy.
    Partin AW; Piantadosi S; Subong EN; Kelly CA; Hortopan S; Chan DW; Wolfert RL; Rittenhouse HG; Carter HB
    Prostate Suppl; 1996; 7():35-9. PubMed ID: 8950362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Free/Total PSA (F/T ratio) kinetics in patients with clinically localized prostate cancer undergoing radical prostatectomy.
    Gregorakis AK; Malovrouvas D; Stefanakis S; Petraki K; Scorilas A
    Clin Chim Acta; 2005 Jul; 357(2):196-201. PubMed ID: 15936010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Total and free PSA kinetics in patients without prostate cancer undergoing radical cystoprostatectomy.
    Gregorakis AK; Stefanakis S; Malovrouvas D; Petraki K; Gourgiotis D; Scorilas A
    Prostate; 2008 May; 68(7):759-65. PubMed ID: 18213630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Is radical prostatectomy a suitable model for determination of PSA half-life?].
    Brändle E; Gottfried HW; Maier S; Flohr P; Steinbach G; Hautmann RE
    Urologe A; 1995 Sep; 34(5):419-23. PubMed ID: 7483161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of preoperative serum cell-free circulating DNA in men with prostate cancer undergoing radical prostatectomy.
    Bastian PJ; Palapattu GS; Yegnasubramanian S; Lin X; Rogers CG; Mangold LA; Trock B; Eisenberger M; Partin AW; Nelson WG
    Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5361-7. PubMed ID: 17875764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of post-radical prostatectomy pathological outcome for stage T1c prostate cancer with percent free prostate specific antigen: a prospective multicenter clinical trial.
    Southwick PC; Catalona WJ; Partin AW; Slawin KM; Brawer MK; Flanigan RC; Patel A; Richie JP; Walsh PC; Scardino PT; Lange PH; Gasior GH; Parson RE; Loveland KG
    J Urol; 1999 Oct; 162(4):1346-51. PubMed ID: 10492194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer.
    Han M; Partin AW; Zahurak M; Piantadosi S; Epstein JI; Walsh PC
    J Urol; 2003 Feb; 169(2):517-23. PubMed ID: 12544300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of modeled PSA clearance on biochemical relapse free survival after radical prostatectomy.
    You B; Girard P; Paparel P; Freyer G; Ruffion A; Charrié A; Hénin E; Tod M; Perrin P
    Prostate; 2009 Sep; 69(12):1325-33. PubMed ID: 19475643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preoperative serum prostate specific antigen levels between 2 and 22 ng./ml. correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng./ml.
    Stamey TA; Johnstone IM; McNeal JE; Lu AY; Yemoto CM
    J Urol; 2002 Jan; 167(1):103-11. PubMed ID: 11743285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Natural history of disease progression in patients who fail to achieve an undetectable prostate-specific antigen level after undergoing radical prostatectomy.
    Rogers CG; Khan MA; Craig Miller M; Veltri RW; Partin AW
    Cancer; 2004 Dec; 101(11):2549-56. PubMed ID: 15470681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcome and complications of radical prostatectomy in patients with PSA <10 ng/ml: comparison between the retropubic, perineal and laparoscopic approach.
    Salomon L; Levrel O; Anastasiadis AG; Saint F; de La Taille A; Cicco A; Vordos D; Hoznek A; Chopin D; Abbou CC
    Prostate Cancer Prostatic Dis; 2002; 5(4):285-90. PubMed ID: 12627213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radical prostatectomy for incidental (stage T1a-T1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence.
    Capitanio U; Scattoni V; Freschi M; Briganti A; Salonia A; Gallina A; Colombo R; Karakiewicz PI; Rigatti P; Montorsi F
    Eur Urol; 2008 Jul; 54(1):118-25. PubMed ID: 18314255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radical prostatectomy for clinical stage T3a disease.
    Freedland SJ; Partin AW; Humphreys EB; Mangold LA; Walsh PC
    Cancer; 2007 Apr; 109(7):1273-8. PubMed ID: 17315165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is preoperative serum prostate-specific antigen level significantly related to clinical recurrence after radical retropubic prostatectomy for localized prostate cancer?
    Haukaas SA; Halvorsen OJ; Daehlin L; Hostmark J; Akslen LA
    BJU Int; 2006 Jan; 97(1):51-5. PubMed ID: 16336328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deoxyribonucleic acid ploidy and serum prostate specific antigen predict outcome following salvage prostatectomy for radiation refractory prostate cancer.
    Amling CL; Lerner SE; Martin SK; Slezak JM; Blute ML; Zincke H
    J Urol; 1999 Mar; 161(3):857-62; discussion 862-3. PubMed ID: 10022701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Percent free prostate specific antigen is not an independent predictor of organ confinement or prostate specific antigen recurrence in unscreened patients with localized prostate cancer treated with radical prostatectomy.
    Graefen M; Karakiewicz PI; Cagiannos I; Hammerer PG; Haese A; Palisaar J; Huland E; Scardino PT; Kattan MW; Huland H
    J Urol; 2002 Mar; 167(3):1306-9. PubMed ID: 11832719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Similar rates of exponential decrease in serum concentrations of free prostate-specific antigen (PSA), PSA complexed to alpha-1-antichymotrypsin, and human glandular kallikrein 2 (hK2) in prostate cancer patients treated with GnRH-analogues.
    Björk T; Schalken J; Wittjes W; Ljungberg B; Lilja H
    Prostate; 2001 Apr; 47(1):14-20. PubMed ID: 11304725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years.
    Amling CL; Blute ML; Bergstralh EJ; Seay TM; Slezak J; Zincke H
    J Urol; 2000 Jul; 164(1):101-5. PubMed ID: 10840432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of perioperative blood transfusion on prostate cancer recurrence.
    Ford BS; Sharma S; Rezaishiraz H; Huben RS; Mohler JL
    Urol Oncol; 2008; 26(4):364-7. PubMed ID: 18367097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Percent of cores positive for cancer is a better preoperative predictor of cancer recurrence after radical prostatectomy than prostate specific antigen.
    San Francisco IF; Regan MM; Olumi AF; DeWolf WC
    J Urol; 2004 Apr; 171(4):1492-9. PubMed ID: 15017206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.